Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Cellectar Biosciences reported strong second quarter 2026 results, highlighted by initiation of site activation for the confirmatory Phase 3 trial of iopofosine I 131 in Waldenström Macroglobulinemia, planned NDA submission under FDA's Accelerated Approval Program in mid-2027, positive Phase 2b CLOVER WaM data, and ongoing Phase 1b trial enrollment…
Liminatus Pharma, a biopharmaceutical company, announced its stock was transferred to the Nasdaq Capital Market and that it received an extension until September 3, 2026, to regain compliance with Nasdaq's minimum bid price requirement. The company intends to take necessary actions to comply while continuing its clinical development in cancer thera…
Pelthos Therapeutics announced its Q2 2026 financial results highlighting a 45% quarter-over-quarter increase in net product revenue for Zelsuvmi, reaching $15.4 million. The company has surpassed 25,000 patients prescribed since launching Zelsuvmi in July 2025 and expects continued growth. It secured a $50 million credit facility to support commer…
MKS (MKSI) sits at the intersection of secular AI build-out and legacy industrial cycles. Recent plant expansions in China and Malaysia and steady free cash flow position the company to capture AI-driven demand for advanced packaging, PCBs and wafer-level processes. At a market cap near $20.7B and a valuation that reflects cyclical variability rath…
With the US-Iran war continuing and supply cuts mounting, global oil inventories offer limited clarity on how long markets could be shielded from a prolonged disruption. Agencies and consultancies cite large headline stockpiles, but the volume that can actually be tapped is smaller and vulnerable, particularly for diesel and jet fuel. Key uncertain…
POET Technologies Inc. reported a 112% year-over-year revenue increase in Q2 2026, marking its sixth consecutive quarter of sequential growth. The net loss narrowed compared to prior quarters, bolstered by a substantial $400 million financing completed in May, enhancing the company's balance sheet and enabling manufacturing capacity expansion. POET…
Chicago Atlantic BDC, Inc., a NASDAQ-listed specialty finance company focusing on direct loans primarily to privately held middle-market companies in the cannabis sector, announced a quarterly cash dividend of $0.34 per share for Q3 2026. The dividend record date is September 25, 2026, with payment on October 9, 2026. The company emphasizes maximiz…
Victoria's Secret & Co. (NYSE: VSXY) announces its second quarter 2026 earnings release and invites investors and analysts to participate in a live webcast conference call scheduled for September 3, 2026. The company provides details about accessing the webcast and highlights its business segments, including Victoria's Secret, PINK, and Adore Me. A…
Parabilis Medicines reported progress in its clinical programs, especially zolucatetide—an investigational direct inhibitor targeting the β-catenin:TCF interaction in multiple Wnt/β-catenin-driven diseases. The company plans to initiate a Phase 3 registrational trial for desmoid tumors in early 2027. Parabilis also announced a major collaboration w…
LENSAR, Inc. reported its second quarter 2026 financial results, highlighting an 18% increase in total revenue and a 20% growth in recurring revenue compared to the same period last year. The company placed 10 new ALLY Robotic Cataract Laser Systems during the quarter, increasing the installed base to 445 systems. Net income turned positive at $3.5…
The Scotts Miracle-Gro Company is collaborating with America250 to bring the 'Our American Story' Airstream mobile studio to ScottsMiracle-Gro Field in Columbus, Ohio, as part of the nation's 250th anniversary celebrations. The initiative aims to collect oral and visual histories that highlight Ohio's cultural and historical influence in America. T…
Legence Corp. reported strong second quarter 2026 financial results with record revenues of $1.26 billion, a 111% increase year-over-year, driven by solid organic growth and the Bowers acquisition. Adjusted EBITDA more than doubled to $154.6 million. The company also reported record backlog and awarded contracts totaling $5.67 billion, a 105% incre…
ProQR Therapeutics reported positive Phase 1 target engagement data for AX-0810, marking the first clinical validation of its proprietary Axiomer RNA editing platform targeting NTCP modulation for cholestatic diseases. The company outlined a robust pipeline with upcoming clinical milestones including Phase 1 data for AX-0811, initiation of biliary …
Aebi Schmidt Group reported a 22% increase in adjusted EBITDA and a 16% growth in order intake for Q2 2026 compared to Q2 2025, alongside a 9% rise in net sales. The company attributes its improved profitability to operational improvements and an expanded market footprint, with strong performance in North America and Europe. Net income turned posit…
Tilray Brands' Montauk Brewing Company announced a partnership with Morning Brew Inc. to release The Morning Brew, a limited-edition light blonde ale. This collaboration enhances Montauk Brewing’s brand presence and leverages Morning Brew’s media influence, with plans for ongoing promotional activities leading up to the 2026 New York City Marathon.
Nutriband Inc.'s CEO Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit focusing on the company's AVERSA™ abuse-deterrent transdermal technology designed to prevent abuse and accidental exposure of drugs like fentanyl. The technology is covered by broad international patents and aims to improve safety profiles of transdermal drug…
Aveanna Healthcare Holdings Inc. announced strong financial results for Q2 2026, with revenue increasing 13.7% year-over-year to $670.5 million and adjusted EBITDA rising 8.0% to $95.4 million. The company raised its full-year 2026 revenue guidance to over $2.68 billion and adjusted EBITDA guidance to over $365 million, citing strong performance ac…
YXT.com Group Holding Limited reported a 6% revenue increase to RMB162.1 million (US$23.9 million) for the first half of 2026 compared to the previous year. The company achieved a higher gross margin of 70.1% and significantly reduced its net loss by over 80% to RMB14.4 million (US$2.1 million). Growth is attributed to AI-native transformation and …
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on breast cancer therapies, announced the appointment of Jason O’Byrne as Chief Financial Officer. With a strong background in biotech finance and operations, O’Byrne will support Olema as it approaches key clinical data readouts and prepares for its initial commercial launch…
FactSet has announced a quarterly cash dividend of $1.16 per share, payable on September 17, 2026, to shareholders of record as of August 31, 2026. The company continues to demonstrate commitment to delivering value to shareholders amid its ongoing provision of financial intelligence and AI solutions globally.
MediWound Ltd. reported second quarter 2026 financial results, highlighting progress in its EscharEx® Phase III VALUE trial targeting chronic wounds and a strengthened commercial agreement with Vericel under a BARDA contract for its burn treatment product NexoBrid®. Revenue for Q2 2026 was $3.1 million, with full-year guidance reaffirmed at $24-26 …
Chicago Atlantic BDC, Inc. reported its second quarter 2026 financial results, highlighting a stable portfolio with no non-accrual loans and a weighted average yield of 16.0% on debt investments. The company ended the quarter with $73.9 million in liquidity and a $1.1 billion pipeline. It declared a third quarter dividend of $0.34 per share. Additi…
Zenas BioPharma announced FDA acceptance of its Biologics License Application (BLA) for obexelimab treating IgG4-Related Disease, with a PDUFA target action date of May 27, 2027. The company confirmed bioequivalence of obexelimab delivery methods, plans a European submission, and expects Phase 2 topline data for Systemic Lupus Erythematosus in Q4 2…
Pyxis Oncology reported its Q2 2026 financial results and highlighted progress in its MICVO clinical programs targeting recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The company completed a private placement raising approximately $50 million upfront, extending its cash runway into Q2 2027. Updated data from Phase 1 monothe…
American Shared Hospital Services (AMS) reported a 19% increase in total revenue to $8.4 million in Q2 2026, fueled by a 40% rise in Direct Patient Services revenue and 22% growth in Proton Beam Radiation Therapy. The company generated $4.4 million in operating cash flow in the first half of 2026 and strengthened its cash position to $6.8 million. …
